TuHURA Biosciences (HURA) 10-K2017 FY Annual report

Filed: 27 Sep 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abdominal, absorbed, adept, adolescent, advisor, Ambit, API, arrest, bendamustine, bloating, boundary, branded, breast, BScN, cancerin, cancersin, carboplatin, cellular, cerebral, cervix, childhood, clearance, colorectal, combinatorial, Computervision, COO, correct, corrected, crosslink, CSF, cyclophosphamide, Cyntellect, description, designedto, died, digital, disclaim, disposition, distant, double, driven, Duke, easily, enrolledGBM, epithelial, Ernst, Exemplar, expressionin, Fig, filer, flavor, fluid, Franklin, FRI, futility, gamma, gynecological, HGSOC, Importantly, indigestion, inevitable, interstrand, Intrexon, Johnson, Jolla, Keytruda, La, leaving, Legacy, line, lock, Luxemburg, lyophilized, mainstay, Mateo, mentioned, modelsin, MSI, mutant, NCCN, nivolumab, OEA, olaparibin, onResponse, Opdivo, ORR, outlook, Parkway, PDUFA, peak, pecuniary, pelvic, pembrolizumab, Penwest, phenotype, pleasure, problem, PSU, Pt, RECIST, reconstituted, Redline, regular, REPROVe, resolution, Rupert, Saiid, salary, SCC, SE, segregation, Senomyx, sensitive, sensitivity, Solving, spinal, spleen, stalling, statusin, stay, strand, subset, Switzerland, synergism, testicular, theseconsolidated, topoisomerase, unamended, uplisting, User, visualization, vitroandin, withRecurrentPlatinumResistantOvarian, worsen, WT, XI, XII, Young, Zarrabian

Removed: accountable, add, aged, agreeing, aim, AML, approvable, assign, Boston, Boylston, broker, climate, compensate, contractor, covenant, detect, detecting, diet, dispose, dysfunctional, eliminate, enabled, entitling, exceeding, expanded, expired, exploring, FASB, finder, Garner, Gleevec, Gray, highlight, implicated, integrated, liquid, MA, markdown, markup, men, Ministry, nation, Nationwide, ninety, Nutrition, partnership, Pharmacopoeia, pollution, proper, purity, redeemed, reliable, reliant, robust, rural, selective, shrink, sixty, smoking, step, subscription, suited, survey, therapeutically, transfer, Union, urban, USP, viable, water, William

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

HURA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of DelMar Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the fiscal year ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey Bacha, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: September 27, 2017	By:	/s/ Jeffrey Bacha
		Jeffrey Bacha
		Chief Executive Officer